Patents by Inventor Gouliang Zhang

Gouliang Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE
    Publication number: 20180127412
    Abstract: The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1,8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 10, 2018
    Inventors: Gouliang ZHANG, Changyou ZHOU
  • NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
    Publication number: 20180072716
    Abstract: Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase and for treating diseases or disorders mediated thereby.
    Type: Application
    Filed: April 8, 2016
    Publication date: March 15, 2018
    Inventors: Hexiang WANG, Gouliang ZHANG, Yunhang GUO, Bo REN, Zhiwei WANG, Changyou ZHOU
  • Fused tricyclic amide compounds as multiple kinase inhibitors
    Patent number: 9670231
    Abstract: Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: June 6, 2017
    Assignee: BeiGene, Ltd.
    Inventors: Changyou Zhou, Gouliang Zhang